As of June 30, 2026, SK Biopharmaceuticals Co., Ltd. carries a market capitalization of 6.78T, placing it among publicly traded companies globally. Its enterprise value stands at 6.45T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.78T |
| Enterprise Value | 6.45T |
SK Biopharmaceuticals Co., Ltd.'s next confirmed earnings release is scheduled for February 10, 2027.
| Earnings Date | 2/10/2027 |
As of June 30, 2026, SK Biopharmaceuticals Co., Ltd. has 78.31M shares outstanding.
| Shares Outstanding | 78.31M |
As of June 30, 2026, SK Biopharmaceuticals Co., Ltd. trades at a trailing price-to-earnings ratio of 16.91. The price-to-sales ratio is 7.87, and the price-to-book ratio stands at 6.64.
| PE Ratio | 16.91 |
| PS Ratio | 7.87 |
| PB Ratio | 6.64 |
| P/TBV Ratio | 7.02 |
| P/FCF Ratio | 31.28 |
| P/OCF Ratio | 27.29 |
As of June 30, 2026, SK Biopharmaceuticals Co., Ltd. trades at an EV/EBITDA multiple of 20.21 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 21.27 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 6.45T versus a market cap of 6.78T, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 7.49 |
| EV / EBITDA | 20.21 |
| EV / EBIT | 21.27 |
As of June 30, 2026, SK Biopharmaceuticals Co., Ltd. maintains a current ratio of 2.72, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.78, indicating elevated leverage, while an interest coverage ratio of 57.16 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.72 |
| Quick Ratio | 1.18 |
| Debt / Equity | 4.78 |
| Debt / EBITDA | 0.15 |
| Interest Coverage | 57.16 |
Over the twelve months ended June 30, 2026, SK Biopharmaceuticals Co., Ltd. posted a return on equity (ROE) of 49.59, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 33.81, measuring how efficiently the asset base is converted into earnings. The company generates approximately 3.19B in revenue per employee across its workforce of 270.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.51 indicates how many times SK Biopharmaceuticals Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 49.59 |
| Return on Assets (ROA) | 33.81 |
| Revenue Per Employee | 3.19B |
| Employee Count | 270.25 |
| Inventory Turnover | 0.51 |
Over the twelve months ended June 30, 2026, SK Biopharmaceuticals Co., Ltd. recorded an income tax benefit of -102.70B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 289.21B, leaving 400.96B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | -102.70B |
As of the close on November 17, 2026, SK Biopharmaceuticals Co., Ltd.'s stock has declined approximately 31.70% over the past 52 weeks. The 50-day moving average sits at 79,162.00, while the 200-day moving average is 91,253.50.
| 52-Week Price Change | -31.70% |
| 50-Day Moving Average | 79,162.00 |
| 200-Day Moving Average | 91,253.50 |
Over the twelve months ended June 30, 2026, SK Biopharmaceuticals Co., Ltd. generated 861.34B in revenue and converted that into 400.96B in net income, yielding earnings per share of 5,004.34. EBITDA reached 319.12B, while operating income came in at 303.22B.
| Revenue | 861.34B |
| Gross Profit | 809.49B |
| Operating Income | 303.22B |
| Pretax Income | 289.21B |
| Net Income | 400.96B |
| EBITDA | 319.12B |
| EBIT | 303.22B |
| Earnings Per Share (EPS) | 5,004.34 |
As of June 30, 2026, SK Biopharmaceuticals Co., Ltd. holds 381.87B in cash and equivalents against 48.83B in total debt, resulting in a net debt position of -379.97B. Total book value stands at 1.02T, with working capital of 554.94B providing operational flexibility.
| Cash & Cash Equivalents | 381.87B |
| Total Debt | 48.83B |
| Net Debt | -379.97B |
| Equity (Book Value) | 1.02T |
| Book Value Per Share | 13,047.10 |
| Working Capital | 554.94B |
SK Biopharmaceuticals Co., Ltd. produced 248.48B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -31.68B in capital expenditures, free cash flow totaled 216.80B - equivalent to 2,768.39 per share.
| Operating Cash Flow | 248.48B |
| Capital Expenditures | -31.68B |
| Free Cash Flow | 216.80B |
| FCF Per Share | 2,768.39 |
Over the twelve months ended June 30, 2026, SK Biopharmaceuticals Co., Ltd. posted a gross margin of 93.98, reflecting its pricing power and cost economics. The operating margin of 35.20 and net profit margin of 46.55 provide insight into operational efficiency.
| Gross Margin | 93.98 |
| Operating Margin | 35.20 |
| Pretax Margin | 33.58 |
| Profit Margin | 46.55 |
| EBITDA Margin | 37.05 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 3.20, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.57, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to SK Biopharmaceuticals Co., Ltd. shareholders.
| Shareholder Yield | 0.57 |
| FCF Yield | 3.20 |
As of June 30, 2026, SK Biopharmaceuticals Co., Ltd. has an Altman Z-Score of 11.94, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 11.94 |
Already premium?